139 related articles for article (PubMed ID: 33111018)
1. Partial Least-Squares Discriminant Analysis and Ensemble-Based Flexible Docking of PD-1/PD-L1 Inhibitors: A Pilot Study.
Kuang Z; Heng Y; Huang S; Shi T; Chen L; Xu L; Mei H
ACS Omega; 2020 Oct; 5(41):26914-26923. PubMed ID: 33111018
[TBL] [Abstract][Full Text] [Related]
2. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
[TBL] [Abstract][Full Text] [Related]
4. Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation.
Liang J; Wang B; Yang Y; Liu B; Jin Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674800
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
6. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X; Lu X; Luo G; Xiang H
Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
Ashizawa T; Iizuka A; Tanaka E; Kondou R; Miyata H; Maeda C; Sugino T; Yamaguchi K; Ando T; Ishikawa Y; Ito M; Akiyama Y
Biomed Res; 2019; 40(6):243-250. PubMed ID: 31839668
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.
Skalniak L; Zak KM; Guzik K; Magiera K; Musielak B; Pachota M; Szelazek B; Kocik J; Grudnik P; Tomala M; Krzanik S; Pyrc K; Dömling A; Dubin G; Holak TA
Oncotarget; 2017 Sep; 8(42):72167-72181. PubMed ID: 29069777
[TBL] [Abstract][Full Text] [Related]
10. Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor.
Puopolo T; Li H; Gutkowski J; Cai A; Seeram NP; Ma H; Liu C
Bio Protoc; 2023 Aug; 13(15):e4765. PubMed ID: 37575393
[TBL] [Abstract][Full Text] [Related]
11. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
Chen T; Li Q; Liu Z; Chen Y; Feng F; Sun H
Eur J Med Chem; 2019 Jan; 161():378-398. PubMed ID: 30384043
[TBL] [Abstract][Full Text] [Related]
12. Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Qin M; Cao Q; Zheng S; Tian Y; Zhang H; Xie J; Xie H; Liu Y; Zhao Y; Gong P
J Med Chem; 2019 May; 62(9):4703-4715. PubMed ID: 30964291
[TBL] [Abstract][Full Text] [Related]
13. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
14. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
Shaabani S; Huizinga HPS; Butera R; Kouchi A; Guzik K; Magiera-Mularz K; Holak TA; Dömling A
Expert Opin Ther Pat; 2018 Sep; 28(9):665-678. PubMed ID: 30107136
[TBL] [Abstract][Full Text] [Related]
15. Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents.
Kamal MA; Badary HA; Omran D; Shousha HI; Abdelaziz AO; El Tayebi HM; Mandour YM
ACS Omega; 2023 Sep; 8(37):33242-33254. PubMed ID: 37744828
[TBL] [Abstract][Full Text] [Related]
16. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene, a SERM targets PD-L1: an in-silico study.
Chopra C; Yodun T; Singh H; Singh B; Singh SK; Goutam U
Am J Transl Res; 2023; 15(8):5206-5215. PubMed ID: 37692949
[TBL] [Abstract][Full Text] [Related]
18. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
Almahmoud S; Zhong HA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
[TBL] [Abstract][Full Text] [Related]
19. Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1.
Ahmed M; Ganesan A; Barakat K
BMC Chem; 2022 Jun; 16(1):49. PubMed ID: 35761353
[TBL] [Abstract][Full Text] [Related]
20. Structural Insights of PD-1/PD-L1 Axis: An In silico Approach.
Rohit S; Patel M; Jagtap Y; Shah U; Patel A; Patel S; Solanki N
Curr Protein Pept Sci; 2024 May; ():. PubMed ID: 38706351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
